Check out our most popular compounded medications! Get Started
Morphine Sulfate 270 mg Slow Release Capsules are formulated with Methocel E4M, a controlled-release polymer. This design allows for the gradual release of the active ingredient over an extended period, providing sustained therapeutic effects. This formulation is used to treat various types of pain including chronic, cancer, postoperative, neuropathic, and arthritis pain. The slow release mechanism reduces dosing frequency and improves patient compliance for medications requiring a controlled and prolonged release profile.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Morphine Sulfate 270 mg Slow Release Capsules are a potent, long-acting opioid analgesic designed to manage moderate to severe pain. This formulation is specifically engineered with Methocel E4M, a type of controlled-release polymer, to ensure a steady and consistent release of the active ingredient over an extended period of time. This slow release mechanism allows for sustained therapeutic effects, reduced dosing frequency, and improved patient compliance, particularly for medications requiring a controlled and prolonged release profile.
This formulation is particularly beneficial for patients requiring relief from pain associated with cancer, post-operative discomfort, and chronic pain conditions. However, it is not recommended for patients with acute pain, as the slow release mechanism may not provide immediate pain relief.
Patients should be aware that Morphine Sulfate 270 mg Slow Release Capsules may cause side effects such as drowsiness, dizziness, and confusion. It is advised not to drive or operate machinery while under the influence of this medication. Furthermore, this medication has the potential to be habit-forming and should not be taken for longer than prescribed.
Healthcare providers should be aware that Morphine Sulfate 270 mg Slow Release Capsules may cause respiratory depression and should be used with caution in patients with respiratory conditions. The potential for habit-forming effects should also be considered when prescribing this medication.
If you have any questions or concerns about Morphine Sulfate 270 mg Slow Release Capsules, please do not hesitate to contact us at Bayview Pharmacy. We are here to provide comprehensive information and support to ensure safe and appropriate use of this medication.
Morphine Sulfate 270 mg Slow Release Capsules are a potent analgesic medication indicated for the management of moderate to severe pain. This particular formulation utilizes Methocel E4M, a type of controlled-release polymer, which is designed to gradually release the encapsulated morphine sulfate over an extended period of time. This slow-release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly beneficial for medications requiring a controlled and prolonged release profile.
It is crucial to note that Morphine Sulfate 270 mg Slow Release Capsules should not be administered to patients with known hypersensitivity to morphine or other opioids, or in patients with significant respiratory depression. Regular monitoring for signs of respiratory depression, sedation, and hypotension is recommended. Additionally, vigilance for signs of opioid addiction, abuse, and misuse is necessary.
Special caution is advised when prescribing Morphine Sulfate 270 mg Slow Release Capsules to patients with renal or hepatic impairment, as well as in elderly patients, due to the potential for increased sensitivity or altered pharmacokinetics. Patients should be advised to avoid alcohol and other CNS depressants while taking this medication to prevent potential additive effects. Furthermore, patients should be cautioned to avoid activities requiring mental alertness, such as driving or operating machinery, until they are fully aware of how this medication affects them.
For any further queries or concerns regarding Morphine Sulfate 270 mg Slow Release Capsules, please do not hesitate to reach out.
Morphine Sulfate 270 mg Slow Release Capsules are a potent, extended-release opioid medication designed to manage moderate to severe pain. These capsules are formulated with Methocel E4M, a type of controlled-release polymer. This innovative formulation allows for the gradual release of the encapsulated medication over an extended period, typically 12 hours. This slow release mechanism provides a consistent level of pain relief throughout the day, reducing the need for frequent dosing and enhancing patient compliance.
The capsules are intended for oral administration and can be taken with or without food, once every 12 hours. It is crucial to adhere to the prescribed dosage regimen, as deviations can lead to serious side effects. However, they are not recommended for short-term pain relief, such as pain resulting from an injury or surgery.
Common side effects of Morphine Sulfate 270 mg Slow Release Capsules include nausea, vomiting, constipation, dizziness, drowsiness, and dry mouth. If you experience any of these side effects, it is important to consult your healthcare provider as they may need to adjust your dosage or consider an alternative medication.
Morphine Sulfate 270 mg Slow Release Capsules represent a significant advancement in pain management, offering sustained therapeutic effects for patients dealing with moderate to severe pain. If you have any questions about this medication or its suitability for your condition, please consult your healthcare provider.
Morphine Sulfate 270 mg Slow Release Capsules is a medication formulated with Methocel E4M, a type of controlled-release polymer. This formulation is designed to release the encapsulated medication gradually over an extended period of time.
The controlled-release polymer, Methocel E4M, is designed to release the active ingredient gradually over an extended period of time. This offers sustained therapeutic effects, reduces dosing frequency, and improves patient compliance for medications requiring a controlled and prolonged release profile.
The benefits of using this medication include sustained therapeutic effects due to the gradual release of the active ingredient, reduced dosing frequency, and improved patient compliance due to the controlled and prolonged release profile.
The slow release mechanism works by gradually releasing the active ingredient over an extended period of time. This is achieved through the use of a controlled-release polymer, Methocel E4M, which encapsulates the medication.
Methocel E4M is a type of controlled-release polymer used in the formulation of certain medications. It is designed to encapsulate the active ingredient and release it gradually over an extended period of time.
The dosing frequency of Morphine Sulfate 270 mg Slow Release Capsules is reduced due to its controlled and prolonged release profile. However, the exact dosing schedule should be determined by your healthcare provider based on your specific medical condition and response to treatment.
The therapeutic effect of Morphine Sulfate 270 mg Slow Release Capsules is sustained over an extended period of time due to the gradual release of the active ingredient. This can help to manage pain effectively over a longer period compared to immediate-release formulations.
No, Morphine Sulfate 270 mg Slow Release Capsules should not be broken or crushed. Doing so can release all of the drug at once, increasing the risk of morphine overdose.
If you miss a dose of Morphine Sulfate 270 mg Slow Release Capsules, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
Common side effects of Morphine Sulfate 270 mg Slow Release Capsules may include constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. You should contact your healthcare provider if you experience any side effects that are severe or concerning to you.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
